Barriers to cervical cancer screening exist despite integrating HIV and gynaecological services for HIV-positive women in Poland
Abstract
Objectives: HIV-positive women are at increased risk of HPV infection and cervical cancer. European and national guidelines advise yearly screening for cervical cancer, however due to the lack of a central registration of HIV infected persons there is a gap in offering such care through general healthcare services in many countries, including Poland.
Material and methods: In response to the above limitations, integrated gynaecological care (IGC) was established at the HIV Out-Patient Clinic in Warsaw. We analysed data from January 2007 to May 2014. Logistic regression models were used to identify factors associated with not using IGC by patients.
Results: Two hundred and forty women were registered in the observation period:59.6% infected through sexual contact, 18.7% through IDUs, 19.2 % through unknown causes and 2.5% by other (two were vertically infected). The median follow-up time was 2.35 (IQR 0.9–4.5) years and 78.3% were on combination antiretroviral therapy (cART). In total 145 of the women (60.4%) used IGC, from 72.1% of those registered in 2007 to 27.3% registered in 2014. There were in total 1075 gynaecological visits and 254 cervical cytology tests performed. Seventy-five (51.7%) women were tested for HPV infection. Factors decreasing the odds of not using IGC identified by multivariate regression models were being on cART (OR 0.25 [IQR: 0.10–0.59]; p = 0.003) and longer time of observation (0.69 [0.58–0.83]; p = 0.0001).
Conclusions: The utilisation of IGC was very high, but with a delay in commencing the IGC. Women on cART and with longer periods of follow-up had lower odds of not using IGC. A screening approach for women not yet on cART, or newly registered in the clinics, needs special attention.
Keywords: HIVcervical cancergynaecological careintegrated servicesHPV
References
- Ronco G, Dillner J, Elfström KM, et al. International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014; 383(9916): 524–532.
- Konopnicki D, Manigart Y, Gilles C, et al. High-risk human papillomavirus genotypes distribution in a cohort of HIV-positive women living in Europe: epidemiological implication for vaccination against human papillomavirus. AIDS. 2016; 30(3): 425–433.
- Heard I, Cubie HA, Mesher D, et al. MACH-1 Study Group. Characteristics of HPV infection over time in European women who are HIV-1 positive. BJOG. 2013; 120(1): 41–49.
- Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000; 92(18): 1500–1510.
- Clifford GM, Franceschi S, Keiser O, et al. Swiss HIV Cohort Study. Immunodeficiency and the risk of cervical intraepithelial neoplasia 2/3 and cervical cancer: A nested case-control study in the Swiss HIV cohort study. Int J Cancer. 2016; 138(7): 1732–1740.
- PTN AIDS. Zasady opieki nad osobami zakażonymi HIV. http://www.ptnaids.pl/pliki/zalecenia_2016_uzupelnione.pdf (2016).
- European AIDS Clinical Society Guidelnes. Version 8.1. October 2016. http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html (Accessed 22 November 2016.).
- Nachega JB, Morroni C, Zuniga JM, et al. HIV-related stigma, isolation, discrimination, and serostatus disclosure: a global survey of 2035 HIV-infected adults. J Int Assoc Physicians AIDS Care (Chic). 2012; 11(3): 172–178.
- The People Living with HIV Stigma Index (STIGMA Index) project. HIV-related stigma: late testing, late treatment. A cross analysis of findings from the people living with HIV Stigma Index in Estonia, Moldova, Poland, Turkey, and Ukraine. 2010. http://www.gnpplus.net/images/stories/Rights_and_stigma/2011_HIVStigma_Report_EN.pdf (23 Nov 2013).
- Reference Group to the United Nations on HIV and Injecting Drug Use. Women who inject drugs: A review of their risks, experiences and needs. http://hivhealthclearinghouse.unesco.org/library/documents/women-who-inject-drugs-review-their-risks-experiences-and-needs (Accessed on: 13 Dec 2016).
- Merenstein DJ, Schneider MF, Cox C, et al. Association between living with children and adherence to highly active antiretroviral therapy in the Women's Interagency HIV Study. Pediatrics. 2008; 121(4): e787–e793.
- Niemiec KT, Horban A, Chazan B, et al. [Antiretroviral therapy in pregnant women with HIV]. Ginekol Pol. 1998; 69(11): 820–826.
- Kowalska JD, Kubicka J, Siwak E, et al. Polish Observational Cohort of HIV/AIDS Patients (POLCA) Study Group. Factors associated with the first antiretroviral therapy modification in older HIV-1 positive patients. AIDS Res Ther. 2016; 13: 2.
- Thorsteinsson K, Ladelund S, Jensen-Fangel S, et al. Adherence to the cervical cancer screening program in women living with HIV in Denmark: comparison with the general population. BMC Infect Dis. 2014; 14: 256.
- Stuardo V, Agustí C, Godinez JM, et al. Human papillomavirus infection in HIV-1 infected women in Catalonia (Spain): implications for prevention of cervical cancer. PLoS One. 2012; 7(10): e47755.
- Konopnicki D, Manigart Y, Gilles C, et al. Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women. J Infect Dis. 2013; 207(11): 1723–1729.
- Giorgi Rossi P, Baldacchini F, Ronco G. The Possible Effects on Socio-Economic Inequalities of Introducing HPV Testing as Primary Test in Cervical Cancer Screening Programs. Front Oncol. 2014; 4: 20.
- Smith LW, Khurshed F, van Niekerk DJ, et al. Women's intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program. BMC Public Health. 2014; 14: 1060.
- Arbyn M, Verdoodt F, Snijders PJF, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014; 15(2): 172–183.
- Ursu RG, Onofriescu M, Luca A, et al. The Need for Cervical Cancer Control in HIV-Positive and HIV-Negative Women from Romania by Primary Prevention and by Early Detection Using Clinically Validated HPV/DNA Tests. PLoS One. 2015; 10(7): e0132271.
- Laut KG, Mocroft A, Lazarus J, et al. Eurosida in Eurocoord. Regional differences in self-reported HIV care and management in the EuroSIDA study. J Int AIDS Soc. 2014; 17(4 Suppl 3): 19504.
